

**United States Patent** [19][11] **Patent Number:** **5,476,661**

Pillai et al.

[45] **Date of Patent:** **Dec. 19, 1995**[54] **COMPOSITIONS FOR TOPICAL APPLICATION TO SKIN, HAIR AND NAILS**[75] Inventors: **Sreekumar Pillai**, Wayne; **Suk H. Cho**, Bogota; **Anthony V. Rawlings**, Wyckoff, all of N.J.[73] Assignee: **Elizabeth Arden Co., Division of Conopco, Inc.**, New York, N.Y.[21] Appl. No.: **326,994**[22] Filed: **Oct. 21, 1994**[51] **Int. Cl.**<sup>6</sup> ..... **A61K 7/48**; A61K 7/06; A61K 7/04[52] **U.S. Cl.** ..... **424/401**; 424/61; 424/701; 514/844; 514/846; 514/847[58] **Field of Search** ..... 424/401, 61, 70.1; 514/844, 846, 847[56] **References Cited****U.S. PATENT DOCUMENTS**

4,778,823	10/1988	Kawamata et al.	514/625
4,985,547	1/1991	Yano et al.	536/41
5,175,321	12/1992	Ohashi et al.	554/63
5,198,210	3/1993	Critchley et al.	424/78.03
5,206,020	4/1993	Critchley et al.	424/401

**FOREIGN PATENT DOCUMENTS**

0512814	11/1992	European Pat. Off.
WO91/19479	12/1991	WIPO

**OTHER PUBLICATIONS**Pillai et al., "Epidermal Vitamin D Metabolism, Function, and Regulation", *Advances In Lipid Research*, vol. 24, (1991), pp. 321-341.Bikle et al., "1,25-Dihydroxyvitamin D<sub>3</sub> Production by Human Keratinocytes", *The Journal of Clinical Investigation, Inc.*, vol. 78, (Aug. 1986), pp. 557-566.

Pillai et al., "1,25-Dihydroxyvitamin D Production and

Receptor Binding in Human Keratinocytes Varies with Differentiation", *The Journal of Biological Chemistry*, vol. 263, No. 11, (Apr. 15, 1988), pp. 5390-5395.Hashimoto et al., "Growth-inhibitory Effects of 1,25-Dihydroxyvitamin D<sub>3</sub> on Normal and Psoriatic Keratinocytes", *British Journal of Dermatology*, (1990), vol. 123, pp. 93-98.Morimoto et al., "Topical Administration of 1,25-Dihydroxyvitamin D<sub>3</sub> for Psoriasis: Report of Five Cases", *Calcif Tissue Int.*, vol. 38, (1986), pp. 119-122.MacLaughlin et al., "Cultured Human Keratinocytes Cannot Metabolize Vitamin D<sub>3</sub> to 25-hydroxyvitamin D<sub>3</sub>", *Federation of European Biochemical Societies*, vol. 282, No. 2, (May 1991), pp. 409-411.

Holick, M. F. in "Cutaneous Aging" (edited by A. Kligman), pp. 223-246, Univ. of Tokyo Press, Tokyo, 1988.

Bikle et al., "Squamous Carcinoma Cell Lines Produce 1,25-Dihydroxyvitamin D, but Fail to Respond to Its Differentiating Effect", *The Society for Investigative Dermatology, Inc.*, (1991), p. 435.Okazaki et al., reported in "Role of Ceramide as a Lipid Mediator of 1 $\alpha$ ,25-Dihydroxyvitamin D<sub>3</sub>-induced HL-60 Cell Differentiation", *The Journal of Biological Chemistry*, vol. 265, No. 26, Sep. 15, 1990, pp. 15823-15831.

Calcif Tissue Int, vol. 38 pp. 119-122 (1986).

*Primary Examiner*—Jyothsna Venkat  
*Attorney, Agent, or Firm*—Rimma Mitelman[57] **ABSTRACT**

Compositions for treating skin, hair and nails which contain 25-hydroxycalciferol in combination with a lipid ingredient. The compositions avoid the toxic effects of 1,25-dihydroxycalciferol, yet attain keratinocyte differentiation and provide additional benefits. Also disclosed is a method of improving or preventing the appearance of wrinkled, flaky, aged, photodamaged skin by applying to skin a composition containing in a cosmetically acceptable vehicle 25-hydroxycalciferol and a lipid ingredient.

**5 Claims, No Drawings**